99mTc-MIP-1404 SPECT/CT评估治疗反应:转移性前列腺癌患者的初步研究
该研究回顾性分析28例转移性前列腺癌患者治疗前后99mTc-MIP-1404 SPECT/CT显像,按RECIST 1.1评估CT治疗反应并以SUVmax变化大于30%判定SPECT反应,与基于前列腺特异性抗原的生化反应进行相关性分析。SPECT与生化反应一致率为75%,高于SPECT与CT的57%及CT与生化反应的50%。作者认为该显像工具可能用于监测转移性前列腺癌治疗,需更大规模、理想为前瞻性的试验进一步验证。
要点
- 99mTc-MIP-1404 SPECT与生化反应一致率75%(κ=0.57),高于SPECT与CT的57%(κ=0.40)及CT与生化反应的50%(κ=0.31)。
- SPECT与CT结果不一致最可能源于CT对淋巴结转移及部分骨受累评估的局限性。
- 作者认为该显像工具可能用于监测转移性前列腺癌治疗,需更大规模、理想为前瞻性试验进一步验证。
核心结论
- 99mTc-MIP-1404 SPECT/CT评估的治疗反应与生化反应之间高度一致,提示该显像工具可能用于监测转移性前列腺癌的治疗。
- 作者指出需要更大规模、理想为前瞻性的试验来帮助揭示PSMA表达SPECT显像在这方面的全部潜力。
研究设计与样本
- 回顾性分析28例转移性前列腺癌患者的99mTc-MIP-1404 SPECT/CT扫描,检查于治疗开始前和治疗完成后进行。
- 8例接受雄激素剥夺治疗,10例接受多西他赛治疗,另10例接受外照射放疗。
- 在SPECT/CT的CT图像上按RECIST 1.1标准评估治疗反应;独立于该分析,在代表性肿瘤病灶中量化最大标准化摄取值(SUVmax),以SUVmax差异大于30%判定治疗反应。
- 影像学反应评估与基于前列腺特异性抗原血清水平的生化反应(BR)进行相关性分析。
主要发现
- SPECT与生化反应的一致率为75%(95%CI 0.55-0.89)(Cohen κ=0.57;95%CI 0.29-0.85;P≤0.01)。
- SPECT与CT的一致率为57%(95%CI 0.37-0.76)(κ=0.40;95%CI 0.14-0.65;P≤0.01)。
- CT与生化反应的一致率为50%(95%CI 0.31-0.69)(κ=0.31;95%CI 0.06-0.57;P≤0.05)。
- SPECT与CT之间的不一致结果最可能归因于CT评估淋巴结转移以及骨受累的局限性,骨受累有时在CT扫描上不可检出。
关键数值与推荐
- CT图像上按RECIST 1.1标准评估治疗反应。
- 以代表性肿瘤病灶SUVmax差异大于30%判定SPECT治疗反应。
- 生化反应基于前列腺特异性抗原血清水平。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文为回顾性分析。
- 作者指出需要更大规模、理想为前瞻性的试验来帮助揭示PSMA表达SPECT显像在评估治疗反应方面的全部潜力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: We investigated the role of Tc-MIP-1404 (Progenics Pharmaceuticals, Inc, New York, NY) SPECT/CT of PSMA expression in the assessment of treatment response in patients with metastatic prostate cancer. METHODS: We retrospectively analyzed Tc-MIP-1404 SPECT/CT scans from 28 patients with metastatic prostate cancer examined before initiation and after completion of therapy. Eight of these patients had been treated with androgen deprivation therapy, 10 with docetaxel, and another 10 with external beam radiotherapy. On the CT images from SPECT/CT, treatment response was assessed according to RECIST 1.1 criteria; independently from that analysis, maximal standardized uptake values (SUVmax) were quantified in representative tumor lesions and treatment response assumed at differences in SUVmax greater than 30%. Radiographic response assessment was correlated to biochemical response (BR) based on prostate-specific antigen serum levels. RESULTS: The concordance rate between SPECT and BR was 75% (95% confidence interval [CI], 0.55-0.89) (Cohen κ = 0.57; 95% CI, 0.29-0.85; P ≤ 0.01), higher than for that between SPECT and CT with 57% (95% CI, 0.37-0.76) (κ = 0.40; 95% CI, 0.14-0.65; P ≤ 0.01), as well as that between CT and BR with 50% (95% CI, 0.31-0.69) (κ = 0.31; 95% CI, 0.06-0.57, P ≤ 0.05). Discordant findings between SPECT and CT were most likely due to limitations of CT in assessing metastases in lymph nodes, as well as bone involvement, which was sometimes not detectable on CT scans. CONCLUSIONS: The high agreement between treatment response, as assessed by Tc-MIP-1404 SPECT/CT and BR, suggests a possible role of that imaging tool for monitoring treatment in metastatic prostate cancer. Larger, ideally prospective trials are needed to help to reveal the full potential of SPECT imaging of PSMA expression in that regard.
引用
- Schmidkonz C, Cordes M, Beck M, et al. Assessment of Treatment Response by 99mTc-MIP-1404 SPECT/CT: A Pilot Study in Patients With Metastatic Prostate Cancer. Clin Nucl Med. 2018. PMID: 29916921. doi:10.1097/RLU.0000000000002162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。